Welcome to our dedicated page for DALRADA FINCL news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on DALRADA FINCL stock.
Dalrada Financial Corporation, through its subsidiaries, provides various products and services in the manufacturing, engineering, and healthcare sectors worldwide. The company offers low-carbon heating and cooling systems, visual inspection kits for detecting cervical cancer, and software solutions in test engineering, accessibility engineering, and more. Additionally, it provides cleaning solutions with electrostatic machines for various facilities. Formerly known as Imaging Technologies Corporation, Dalrada Financial Corporation was incorporated in 1982 and is headquartered in Escondido, California.
The company, under the leadership of CEO Brian Bonar, focuses on driving innovation in the Clean Energy and Health Care sectors. Its segments include Dalrada Climate Technology and Genefic Specialty Pharmacy, offering advanced heat pump technology and end-to-end prescription services, respectively. With a commitment to sustainability and cutting-edge solutions, Dalrada Financial Corporation aims to deliver value to its shareholders.
Dalrada Corporation (OTCQB: DFCO) announces the opening of two new healthcare facilities in California, including the Sòlas Rejuvenation + Wellness clinic and Empower Genomics laboratory. These facilities aim to enhance public access to personalized health solutions and virology testing, including on-site COVID-19 testing. Sòlas offers a range of advanced medical and therapy services in a 56,510-square foot center in Poway, California. The company emphasizes its commitment to addressing global health challenges through innovative solutions and partnerships.
Dalrada Corporation (OTCQB: DFCO) announced the authorization of 10,002 Convertible Series “G” Preferred Shares at a par value of $0.01 each on September 23. This move will convert $6,532,188 from liabilities to Owner’s Equity. The investors agreed to waive penalties and default interest after September 30, 2021. This transaction indicates a positive shift in equity management. Dalrada has made significant advances in technology, engineering, and health sectors, enhancing revenues and operating profits during fiscal year 2021. The company aims to provide innovative solutions across its three divisions.
Dalrada Corporation (DFCO) has signed a letter of intent to acquire Advanced DME Services, also known as Advanced Homecare, a Southern California-based provider focusing on sleep apnea solutions. This strategic acquisition aims to establish a new subsidiary within Dalrada Health, expanding its market reach and enhancing growth opportunities. Advanced Homecare has served nearly 40,000 patients since 2005, and its revenue reached $10 million in 2020. The acquisition aligns with Dalrada's mission to improve healthcare solutions and is backed by coverage from major insurance providers.
Dalrada Corporation (DFCO) has been recognized as one of the Best San Diego-Based Clean Energy Companies. The company aims to innovate solutions for complex problems in clean energy, industrial engineering, health, and wellness. Dalrada's subsidiary, Likido®, received accolades for its innovation and societal impact. Likido® energy solutions focus on reducing greenhouse gas emissions and improving energy efficiency, with products like Likido®ONE and Likido®CRYO. The company emphasizes corporate social responsibility and environmental stewardship.
Dalrada Corporation (DFCO) has established a Clean Energy Advisory Board, featuring significant leaders in climate and business, including former U.S. Secretary of the Interior, Ryan Zinke. The board aims to forge strategic alliances for sustainable development and responsible environmental policies. Zinke emphasizes the importance of energy-efficient technologies that reduce carbon footprints. Dalrada's innovative low-carbon heating and cooling technology utilizes supercritical CO2, aiming to enhance energy efficiency while minimizing emissions.
Dalrada Corporation (OTCQB: DFCO) announced a remarkable 189% revenue surge to $3,406,684 for fiscal year 2021, compared to $1,178,154 in 2020. The growth was fueled by its subsidiaries: Dalrada Health, Dalrada Technology, and Dalrada Precision. Highlights included key acquisitions, product launches, and client expansions. Operating expenses rose to $9,504,869 from $3,241,335 due to increased activity. Despite this, Dalrada reported a net income of $1,221, rebounding from a net loss of $2,477,557 the previous year. The company’s board continues to attract industry leaders to drive innovation.
Dalrada Corporation (OTCQB: DFCO) has announced its community outreach initiative providing free COVID-19 point-of-care tests at events, including the Boise Pride Festival. Pala Diagnostics, a joint venture with Vivera Pharmaceuticals, administered nearly 3,000 rapid antigen and PCR tests, ensuring compliance with health protocols. The collaboration aims to restore safe public gatherings, reflecting the company's commitment to innovative health solutions. As part of its strategy, Dalrada focuses on disruptive solutions across its business divisions to address global challenges.
Dalrada Corporation (OTCQB: DFCO) has announced that its Q1 2022 gross revenues are on track to exceed the combined gross revenues of the last eight quarters, pending review. CEO Brian Bonar emphasized Dalrada's commitment to providing innovative solutions in healthcare, clean energy, and technology. The company aims to meet current healthcare industry needs with affordable and accessible products. Established in 1982, Dalrada focuses on engineering, life sciences, and technology, with subsidiaries dedicated to impactful innovations.
Dalrada Corporation (OTCQB: DFCO) has announced the opening of two new subsidiaries under Dalrada Health. Pala Diagnostics is a national laboratory for COVID-19 testing, providing rapid antigen and PCR testing, while Sòlas Rejuvenation + Wellness offers advanced wellness programs. CEO Brian Bonar emphasized the importance of accurate health testing amidst the ongoing health crisis, highlighting Pala’s CLIA-certified lab's rapid results and mobile services. Dalrada Health aims to improve global health accessibility and affordability.
Dalrada Corporation (OTCQB: DFCO) has announced a joint venture between its subsidiary Dalrada Health and Vivera Pharmaceutical, Inc., creating Pala Diagnostics, LLC. This initiative aims to enhance COVID-19 testing capabilities, providing rapid results and life science testing services. Pala Diagnostics will initially offer EUA-approved rapid antigen tests and lab-based PCR testing. The collaboration seeks to support businesses and educational institutions as they reopen safely. The venture taps into Vivera's extensive healthcare network and expertise in pharmaceuticals and diagnostics.
FAQ
What is the current stock price of DALRADA FINCL (DFCO)?
What is the market cap of DALRADA FINCL (DFCO)?
What products and services does Dalrada Financial Corporation offer?
When was Dalrada Financial Corporation incorporated?
Where is Dalrada Financial Corporation headquartered?
Who is the CEO of Dalrada Financial Corporation?
What are the core segments of Dalrada Financial Corporation?
What is the focus of Dalrada Financial Corporation?
What is the mission of Dalrada Financial Corporation?
